Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.43 |
| ▸ | BUB1 | O43683 | 1/20 | 0.42 |
| ▸ | PRKACG | P22612 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 0.42 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3636323 | 0.83 | BAZ2B (0.45) | — | |
| SCHEMBL3638019 | 0.80 | ATR (0.54) | MAPK14SMYD3 | |
| SCHEMBL3630292 | 0.79 | SCN9A (0.52) | — | |
| SCHEMBL3631738 | 0.77 | HPGD (0.57) | MAPK14CYP2C9MAPK11 | |
| SCHEMBL3635963 | 0.76 | SCN9A (0.42) | — | |
| SCHEMBL3634670 | 0.75 | NPC1 (0.50) | SMYD3 | |
| SCHEMBL3237045 | 0.73 | PRKAB2 (0.50) | SMYD3CNR1 | |
| SCHEMBL3637988 | 0.73 | F2 (0.41) | MAPK14SMYD3 | |
| SCHEMBL17436933 | 0.72 | CCNC (0.58) | MAPK14SMYD3 | |
| SCHEMBL3442327 | 0.71 | RAB9A (0.62) | MAPK14SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155687-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | MAPK14 1609/4885CYP2C9 1204/4885SMYD3 2781/4885 |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | MAPK14 1609/4885CYP2C9 1204/4885SMYD3 2781/4885 |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | MAPK14 1609/4885CYP2C9 1204/4885SMYD3 2781/4885 |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | MAPK14 1609/4885CYP2C9 1204/4885SMYD3 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.